Nijhawan Pardeep 4
4 · Edesa Biotech, Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Edesa Biotech CEO Pardeep Nijhawan Buys Stock, Receives Award
What Happened Pardeep Nijhawan, Chief Executive Officer of Edesa Biotech (EDSA), made open-market purchases and received a grant reported on a Form 4 filed March 2, 2026. He purchased a total of 50,571 shares in two open-market transactions (20,571 shares and 30,000 shares) for a combined reported cash outlay of $99,176. He also was granted 10,016 restricted share units (RSUs) that vested in full upon grant (reported with $0 acquisition price).
Key Details
- Transactions reported: purchases on 2026-02-26 and 2026-02-27; RSU grant on 2026-03-02 (filed 2026-03-02).
- Purchases:
- 20,571 shares on 2026-02-26 at a weighted average $1.58 (total $32,480). Prices ranged $1.54–$1.58 (footnote F1).
- 30,000 shares on 2026-02-27 at a weighted average $2.22 (total $66,696). Prices ranged $2.22–$2.2295 (footnote F3).
- Award: 10,016 RSUs on 2026-03-02, reported at $0.00 and noted as vested in full upon grant under the 2019 Equity Incentive Plan (footnote F2).
- Shares owned after these transactions: not specified in this filing.
- Other disclosures: Mr. Nijhawan reports certain corporate and trust entities (footnotes F4 and F5) and disclaims beneficial ownership of shares held by those entities except to the extent of his pecuniary interest.
Context
- These are outright purchases (a bullish signal in that the insider bought shares) and an equity award that vested immediately. The RSU grant is reported at $0.00 in the filing but represents an issuance of shares under the company plan; the filing does not assign a cash value in Column 4.
- No sale transactions were reported in this filing. The filing does not indicate any 10b5-1 trading plan or tax-withholding share-forfeiture events.
- Retail investors often view insider purchases as more informative than awards; this filing documents modest open-market buying by the CEO totaling about $99K.
Insider Transaction Report
Form 4
Nijhawan Pardeep
DirectorChief Executive Officer10% Owner
Transactions
- Purchase
Common Shares
[F1]2026-02-26$1.58/sh+20,571$32,480→ 615,797 total - Award
Common Shares
[F2]2026-03-02+10,016→ 625,813 total - Purchase
Common Shares
[F3][F4]2026-02-27$2.22/sh+30,000$66,696→ 371,702 total(indirect: Held by Pardeep Nijhawan Medicine Professional Corporation)
Holdings
- 32,609(indirect: By Trust)
Common Shares
[F4] - 32,013(indirect: Held by The Digestive Health Clinic Inc.)
Common Shares
[F5] - 53,104(indirect: Held by 1968160 Ontario Inc.)
Common Shares
[F4]
Footnotes (5)
- [F1]The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
- [F3]The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.2295 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F4]Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F5]Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Signature
/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan|2026-03-02